Abstract
An immunohistochemical analysis for p16 protein was performed in 171 patients with non-small-cell lung cancer (NSCLC). Sixty-two carcinomas (36.3%) were classified as p16-negative. p16-negative tumours in squamous cell carcinomas (SCCs) were significantly more than those in adenocarcinomas (P = 0.039). There was no significant difference in survival according to tumour p16 status in patients with NSCLCs or in patients with adenocarcinomas. In contrast, of patients with SCCs, the 5-year survival rate of patients with p16-negative tumours was significantly lower than those with p16-positive tumours (P = 0.001). Especially, the survival of patients with p16-negative tumours was significantly worse than that of patients with p16-positive tumours in the early stage of the SCC, e.g. stage I (P = 0.005). Multivariate analysis showed that p16 status and nodal status were significant prognostic factors for the survival of patients with SCCs of the lung (P = 0.024 and P = 0.008 respectively). In conclusion, our study showed that alteration of p16 was one of the significant factors of a poor prognosis in SCCs of the lung, and that p16 might play an important role in some SCCs of the lung due to its high prevalence and prognostic value. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Betticher DC, White GRM, Vonlanthen S, Liu X, Kappeler A, Altermatt HJ, Thatcher N and Heighway J (1997) G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer 74: 556–562
Chung GTY, Sundaresan V, Hasleton P, Rudd R, Taylor R and Rabbitts PH (1995) Sequential molecular genetic changes in lung cancer development. Oncogene 11: 2591–2598
Cordon-Cardo C (1995) Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am J Pathol 147: 545–560
Cox DR (1972) Regression models and life-tables. J R Stat Soc B 34: 187–220
Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT and Barrett JC (1995) KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268: 884–886
Folkman J (1990) What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82: 4–6
Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K and Sugimachi K (1997) K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer 75: 1125–1130
Gazzeri S, Gouyer V, Vour’ch C, Brambilla C and Brambilla E (1998) Mechanisms of p16INK4Ainactivation in non-small-cell lung cancers. Oncogene 16: 497–504
Geradts J, Fong KM, Zimmerman PV, Maynard R and Minna JD (1999) Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small-cell lung cancers. Clin Cancer Res 5: 791–800
Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, Sidransky D and Baylin SB (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525–4530
Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Kinoshita M, Hadama T and Miyake M (1998) Mutations of p53 and K- ras genes as prognostic factors for non-small-cell lung cancer. Int J Oncol 12: 553–563
Kaplan EL and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Kashiwabara K, Oyama T, Sano T, Fukuda T and Nakajima T (1998) Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small-cell lung cancers. Int J Cancer 79: 215–220
Kawamata N, Miller CW and Koeffler HP (1995) Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non-small-cell lung cancers. Mol Carcinogen 14: 263–268
Kinoshita I, Dosaka-Akita H, Mishina T, Akie K, Nishi M, Hiroumi H, Hommura F and Kawakami Y (1996) Altered p16INK4and retinoblastoma protein status in non-small-cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res 56: 5557–5562
Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA and Geradts J (1996) Rb and p16INK4aexpression in resected non-small-cell lung tumors. Cancer Res 56: 3415–3420
Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G and Bartek J (1995) Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375: 503–506
Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170
Marchetti A, Buttitta F, Pellegrini S, Bertacca G, Chella A, Carnicelli V, Tognoni V, Filardo A, Angeletti CA and Bevilacqua G (1997) Alterations of p16 (MTS1) in node-positive non-small-cell lung carcinomas. J Pathol 181: 178–182
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686–692
Minna JD (1991) Neoplasms of the lung. In: Principles of Internal Medicine, Isselbacher KJ (ed), pp. 1102–1110. McGraw-Hill: New York
Miyake M, Koyama M, Seno M and Ikeyama S (1991) Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J Exp Med 174: 1347–1354
Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111: 1710–1717
Nakagawa K, Conrad NK, Williams JP, Johnson BE and Kelley MJ (1995) Mechanism of inactivation of CDKN2 and MTS2 in non-small-cell lung cancer and associated with advanced stage. Oncogene 11: 1843–1851
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753–756
Otterson GA, Kratzke RA, Coxon A, Kim YW and Kaye FJ (1994) Absence of p16INK4protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9: 3375–3378
Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T and Kerbel RS (1995) Mutant ras oncogenes up-regulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575–4580
Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J and Sidransky D (1996) High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56: 3630–3633
Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, Cordon-Cardo C and Slamon DJ (1993) Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The lung cancer study group. Oncogene 8: 1913–1919
Rodenhuis S and Slebos RJC (1992) Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52: 2665s–2669s
Rusin MR, Okamoto A, Chorazy M, Czyzewski K, Harasim J, Spillare EA, Hagiwara K, Hussain SP, Xiong Y, Demetrick DJ and Harris CC (1996) Intragenic mutations of the p16INK4, p15INK4Band p18 genes in primary non-small-cell lung cancers. Int J Cancer 65: 734–739
Sakaguchi M, Fujii Y, Hirabayashi H, Yoon HE, Komoto Y, Oue T, Kusafuka T, Okada A and Matsuda H (1996) Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 65: 442–445
Serrano M, Hannon GJ and Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704–707
Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ and Rollins BJ (1995) Reciprocal Rb inactivation and p16INK4expression in primary lung cancers and cell lines. Cancer Res 55: 505–509
Shimizu T and Sekiya T (1995) Loss of heterozygosity at 9p21 loci and mutations of theMTS1 and MTS2genes in human lung cancers. Int J Cancer 63: 616–620
Taga S, Osaki T, Ohgami A, Imoto H, Yoshimatsu T, Yoshino I, Yano K, Nakanishi R, Ichiyoshi Y and Yasumoto K (1997) Prognostic value of the immunohistochemical detection of p16INK4expression in non-small cell lung carcinoma. Cancer 80: 389–395
Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF and Minna JD (1989) p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491–494
Tanaka H, Fujii Y, Hirabayashi H, Miyoshi S, Sakaguchi M, Yoon HE and Matsuda H (1998) Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int J Cancer 79: 111–115
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM and Bos JL (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525–532
Volm M, Koomagi R and Mattern J (1998) Prognostic value of p16INK4Aexpression in lung adenocarcinoma. Anticancer Res 18: 2309–2312
Vonlanthen S, Heighway J, Tschan MP, Borner MM, Altermatt HJ, Kappeler A, Tobler A, Fey MF, Thatcher N, Yarbrough WG and Betticher DC (1998) Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small-cell lung cancer and correlates with p53 overexpression. Oncogene 17: 2779–2785
Vos S, Miller CW, Takeuchi S, Gombart AF, Cho SK and Koeffler HP (1995) Alterations of CDKN2 (p16) in non-small-cell lung cancer. Gene Chromosome Canc 14: 164–170
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Huang, CI., Taki, T., Higashiyama, M. et al. p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung. Br J Cancer 82, 374–380 (2000). https://doi.org/10.1054/bjoc.1999.0929
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0929
Keywords
This article is cited by
-
Metastatic HPV-Associated Oropharyngeal Versus Primary Pulmonary Squamous Cell Carcinoma: is p16 Immunostain Useful?
Head and Neck Pathology (2020)
-
Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach
Modern Pathology (2005)
-
Alterations of tumor suppressor genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer
Annals of Nuclear Medicine (2003)